Deals between pharmaceutical companies and the U.S. government to reduce drug prices are likely to drive higher costs for new medicines in Switzerland over time, according to Thomas Schinecker, CEO of ...

FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo ZURICH, Dec 20 (Reuters) - Deals between ...

The agreement includes $25 million in upfront and near-term payments and could bring Caris up to $1.1 billion in milestone payments tied to research, development and sales, the companies said. Sign up ...

EXTON, PA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Following this week’s European Commission approval of Roche/Genentech’s Gazyvaro (obinutuzumab) for the treatment of lupus nephritis (LN), Spherix Global ...

The MarketWatch News Department was not involved in the creation of this content. EXTON, PA, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first wave of Launch Dynamix(TM) ...

EXTON, PA, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first wave of Launch Dynamix™: Gazyva in Lupus Nephritis, providing the earliest independent read on the ...

Turns out, Chronic Fatigue Syndrome (CFS) and long Covid have a few things in common. For one, they're notoriously tricky to diagnose. So when researchers said they developed a blood test that may be ...

Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Fenebrutinib appears effective at treating both relapsing multiple sclerosis and primary progressive ...

Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Fenebrutinib appears effective at treating both relapsing multiple sclerosis and primary progressive ...

Genentech was hit with a whistleblower retaliation and disability discrimination lawsuit on Nov. 7 in Oregon Circuit Court for Washington County. The action, brought by Oldham Law Office on behalf of ...

Roche’s Genentech unit is laying off staff at its Bay Area headquarters for at least the third time this year, saying goodbye to 118 employees in a workforce reduction that spans multiple departments.

(KRON) — Genentech, a biotechnology company based in South San Francisco, is set to permanently lay off 118 employees, according to a Worker Adjustment and Retraining Notification (WARN) notice. Meta ...